top of page
iStock-1125084447.jpg

Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia.

September 2024

AdobeStock_170601825_edited.jpg

Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001.

May 2024

Image by Justin Case

Vesper Bio awarded grant by The Michael J. Fox Foundation to assess sortilin inhibitors in the treatment of Parkinson’s disease.

January 2024

AdobeStock_456930385_edited.jpg

Phase I study underway as first volunteer dosed with VES001, a first-in-class oral treatment for Frontotemporal Dementia.

December 2023

bottom of page